000			03407cam a2200349 a 4500
003			EG-GiCUC
005			20250223032125.0
008			181129s2018 ua dh f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.11.18.M.Sc.2018.Da.S
100	0		_aDalia Mohamed Mohamed Abdelrhman
245	1	0	_aStudy the correlation between tumor necrosis factor Alpha (TNF-Ü) gene polymorphism and the development of FVIII inhibitors In Egyptian hemophilia a patients / _cDalia Mohamed Mohamed Abdelrhman ; Supervised Alia Abdelaziz Saad Ayad , Hoda Ali Sadek , Doaa M. Eldemerdash
246	1	5	_aدراسة العلاقة بين تعدد الشكل الجيني لعامل نخر الورم ألفا و تكون مثبطات عامل التجلط الثامن في المرضى المصريين المصابين بهيموفيليا ألف
260			_aCairo : _bDalia Mohamed Mohamed Abdelrhman , _c2018
300			_a148 P. : _bcharts , facsimiles ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine
520			_aBackground : The development of alloantibodies (inhibitors) against the transfused factor VIII in Hemophilia A patients is the most serious therapy complication. The pathophysiology of their formation is still unknown. Many cytokines, including tumor necrosis factor-Ü (TNF-Ü), may play a role in the perpetuation of such complication. Aim of the Work: The aim of this study is to evaluate the influence of TNF-Ü gene polymorphism (308G/A) on the development of FVIII inhibitors. Also, the effects of some treatment related risk factors of the formation of FVIII inhibitors in multi-transfused hemophilia A patients.Patients and methods: Fifty patients with moderate to severe hemophilia A were examined for existence of FVIII inhibitors by Bethesda method, and classified into 25 patients positive inhibitor group and 25 patients negative inhibitor group. In addition, all the patients, were genotyped for TNF-Ü gene polymorphisms (308G/A) using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Chi square test and Fisher{u2019}s exact test were used for statistical analysis. Results: The 25 patients developed FVIII inhibitors, 19 patients (76%) had low titer (< 5 BU/ml) and 6 patients (24%) had high titer (> 5BU/ml). The studied treatment related risk factors has no relation with FVIII inhibitor development. No statistically significant correlation was found between the positivity of anti FVIII antibodies and the TNF-Ü gene polymorphism (308A/G) (P =0.426). The difference between positive inhibitor group and negative inhibitor group regarding the genotype frequency of TNF-Ü (308A/G) is not statistically significant (P = 0.083). We did not find a significant correlation between the existence of such polymorphism and any of the studied treatment related risk factors
530			_aIssued also as CD
653		4	_aFVIII inhibitors
653		4	_aHemophilia A
653		4	_aTNF-Ü (308A/G) gene polymorphism
700	0		_aAlia Abdelaziz Saad Ayad , _eSupervisor
700	0		_aDoaa Mohamed Eldemerdash , _eSupervisor
700	0		_aHoda Ali Sadek , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aEnas _eCataloger
905			_aNazla _eRevisor
942			_2ddc _cTH
999			_c68813 _d68813